Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF347 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal TRAILR1/TNFRSF10A Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human TRAIL R1/TNFRSF10A in Western blots. In Western blots, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R2 is observed and no cross-reactivity with rhTRAIL R3 and rhTRAIL R4 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Biotin
- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, Perego P
The Journal of pharmacology and experimental therapeutics 2014 Mar;348(3):360-71
The Journal of pharmacology and experimental therapeutics 2014 Mar;348(3):360-71
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, Shamimi-Noori SM, Maxhimer JB, Schrump DS, Nguyen DM
Apoptosis : an international journal on programmed cell death 2007 Jan;12(1):55-71
Apoptosis : an international journal on programmed cell death 2007 Jan;12(1):55-71
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
Tsai WS, Yeow WS, Chua A, Reddy RM, Nguyen DM, Schrump DS, Nguyen DM
Molecular cancer therapeutics 2006 Dec;5(12):2977-90
Molecular cancer therapeutics 2006 Dec;5(12):2977-90
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Mouzakiti A, Packham G
British journal of haematology 2003 Jul;122(1):61-9
British journal of haematology 2003 Jul;122(1):61-9
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Mouzakiti A, Packham G
British journal of haematology 2003 Jul;122(1):61-9
British journal of haematology 2003 Jul;122(1):61-9
No comments: Submit comment
No validations: Submit validation data